XORTX Announces Completion of Dosing in XRX-OXY-101 Clinical Study
December 19, 2022 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Dec. 19, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...
XORTX Announces New Proof of Concept Data in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
December 08, 2022 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Dec. 08, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...
XORTX Announces Completion of Screening and Enrollment in Bridging Pharmacokinetics Study
November 28, 2022 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Nov. 28, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
November 25, 2022 17:45 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Nov. 25, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Therapeutics Appoints Stacy Evans, M.D., MBA as Chief Business Officer
November 16, 2022 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Nov. 16, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Presents New Proof of Concept Data at American Society of Nephrology
November 03, 2022 17:00 ET
|
XORTX Therapeutics Inc.
● Xanthine Oxidase Inhibition with XRx-008 Blocks Uric Acid Induced Increasein Total Kidney Weight in Polycystic Kidney Disease ● CALGARY, Alberta, Nov. 03, 2022 (GLOBE NEWSWIRE) -- XORTX...
XORTX Announces Participation at Upcoming Investor Conferences
November 03, 2022 10:15 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Nov. 03, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...
XORTX Receives Further No Objection Letter from Health Canada
October 26, 2022 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Oct. 26, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...
XORTX Sponsored American Society of Nephrology Study Abstract Available Online
October 25, 2022 07:00 ET
|
XORTX Therapeutics Inc.
• Chronically Increased Uric Acid Accelerates Structuraland Functional Changes in Polycystic Kidney Disease • CALGARY, Alberta, Oct. 25, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc....
XORTX Announces Closing of US$5 Million Public Offering
October 07, 2022 18:02 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Oct. 07, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...